NMR trades 8.3% below Wall Street's consensus target of $10.20.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NMR achieves its forward estimates and maintains a stable P/E multiple of 0.1x. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Nomura Holdings, Inc. (NMR) has a Wall Street consensus price target of $10.20, based on estimates from 9 covering analysts. With the stock currently trading at $9.42, this represents a potential upside of +8.3%. The company has a market capitalization of $27.53B.
Analyst price targets range from a low of $10.20 to a high of $10.20, representing a 0% spread in expectations. The median target of $10.20 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 3 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, NMR trades at a trailing P/E of 12.5x and forward P/E of 0.1x. The forward PEG ratio of 0.00 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +35.4% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $1969.66, with bear and bull scenarios of $1240.88 and $2595.22 respectively. Model confidence stands at 45/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 MSMorgan Stanley | $286.2B | $181.44 | $212.00 | +16.8% | Buy | 14.1x | 53 |
 GSThe Goldman Sachs Group, Inc. | $260.7B | $865.82 | $1130.75 | +30.6% | Hold | 12.1x | 55 |
 UBSUBS Group AG | $156.6B | $47.78 | $23.57 | -50.7% | Buy | 13.0x | 29 |
 DBDeutsche Bank AG | $65.5B | $34.84 | $43.00 | +23.4% | Hold | 10.5x | 33 |
 MUFGMitsubishi UFJ Financial Group, Inc. | $236.5B | $20.97 | — | — | Buy | 0.1x | 2 |
 BACBank of America Corporation | $350.7B | $49.42 | $66.00 | +33.5% | Buy | 11.3x | 54 |
 CCitigroup Inc. | $204.2B | $119.08 | $151.50 | +27.2% | Buy | 10.4x | 27 |
 JPMJPMorgan Chase & Co. | $896.3B | $334.49 | $373.36 | +11.6% | Buy | 13.5x | 61 |
 SMFGSumitomo Mitsui Financial Group, Inc. | $90.3B | $23.31 | — | — | Hold | 0.1x | 4 |
 MFGMizuho Financial Group, Inc. | $114.5B | $9.40 | $10.00 | +6.4% | Hold | 0.1x | 5 |
Quick answers to the most common questions about buying NMR stock.
The consensus price target for NMR is $10.2, close to the current price of $9.42 (8.3% implied move). Based on 9 analyst estimates, the stock appears fairly valued near current levels.
NMR has a consensus rating of "Hold" based on 9 Wall Street analysts. The rating breakdown is mixed, with 6 Hold ratings making up the largest segment. The consensus 12-month price target of $10.2 implies 8.3% upside from current levels.
With a forward P/E of 0.0585x, NMR trades at a relatively low valuation. The consensus target of $10.2 implies 8.3% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $10.2 for NMR, while the most conservative target is $10.2. The consensus of $10.2 represents the median expectation. Our quantitative valuation model projects a bull case target of $2595 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
NMR is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 6 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NMR stock forecast based on 9 Wall Street analysts shows a consensus price target of $10.2, with estimates ranging from $10.2 (bear case) to $10.2 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $1970, with bear/bull scenarios of $1241/$2595.
Our quantitative valuation model calculates NMR's fair value at $1970 (base case), with a bear case of $1241 and bull case of $2595. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 45/100.
NMR trades at a forward P/E ratio of 0.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 12.5x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
NMR appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $10.2 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NMR analyst price targets range from $10.2 to $10.2, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $10.2 consensus represents the middle ground. Our model's $1241-$2595 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.